Therapeutic targets from a Drosophila model of Alzheimer's disease

被引：17

作者：

Crowther, DC ^{[1
]}

Kinghorn, KJ ^{[1
]}

Page, R ^{[1
]}

Lomas, DA ^{[1
]}

机构：

[1] Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2XY, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2004年 / 4卷 / 05期

基金：

英国惠康基金; 英国医学研究理事会;

关键词：

D O I：

10.1016/j.coph.2004.07.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The dominating role of the mouse in modeling Alzheimer's disease has been challenged this year by Drosophila melanogaster. Transgenic flies expressing toxic beta-amyloid peptides develop neurodegeneration. It is these peptides that accumulate in human disease and are thought to be the initiating factor in Alzheimer's disease. The flies exhibit a clear phenotype from a few days of age, including reduced locomotor function, impaired olfactory memory and shortened lifespan. Therapeutic agents that interfere with the generation of toxic aggregates of beta-amyloid peptides have been shown to rescue the flies. Several groups are now using the power and speed of genetic screens in the fly to accelerate the discovery of novel therapeutic agents.

引用

页码：513 / 516

页数：4